View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Alexander Aukner
  • Alexander Aukner

Austevoll Seafood (Buy, TP: NOK108.00) - Set for Peruvian rebound

We expect Q1 EBITDA of NOK1,528m, largely in line with consensus for NOK1,496m (results due at 07:00 CET on 15 May). Ahead of the report we have increased our Q1 EBITDA estimates for Lerøy Seafood and Foodcorp. The first season quota in Peru was 2.5mt, above our estimate of 2.0mt; while some uncertainty remains for catch rates, the proportion of juvenile fish and fat content, we expect more information with the Q1 report. Nevertheless, a normalisation in Peru through 2024 is set to benefit the c...

Patrik Ling
  • Patrik Ling

Oncopeptides (No_rec, TP: SEK) - Rights issue announced

Oncopeptides this morning announced plans for a cSEK300m fully guaranteed rights issue. This should not come as a surprise to the market as the company was very clear in its Q4 report that it had financial resources to last into Q2 2024. Due to DNB Markets’ role in the rights issue, we have withdrawn our target price and recommendation.

Alexander Aukner
  • Alexander Aukner

The quality report

Knowing who has the best farming locations, production areas and operations is key to assessing future performance potential. Our extensive asset quality research findings suggest SalMar has the best sites, and the best MAB portfolio, while Mowi has outperformed its benchmark the most and has the most conservative estimates versus our expectations. Grieg Seafood is the most undervalued and Lerøy Seafood has the highest margin rebound potential in our view.

Alexander Aukner
  • Alexander Aukner

Austevoll Seafood (Buy, TP: NOK108.00) - Salmon better, Pelagia softer

Q4 EBITDA was NOK1,190m, 16–17% above our estimate and consensus, driven by Lerøy Seafood and Austral, while Pelagia fell short of expectations. We have cut our 2024e EPS by 7.3%, driven by Lerøy Seafood, Austral and Pelagia, but increased 2025–2026e by 3.8–6.4%. We reiterate our BUY, but have reduced our target price to NOK108 (111).

Patrik Ling
  • Patrik Ling

Oncopeptides (Hold, TP: SEK5.50) - US not an option, focus on Europe

In line with our base-case scenario, the FDA has withdrawn the accelerated approval for Pepaxto in the US. As a result, the focus is now growth in Europe, where it has full approval. Q4 earnings were weaker than we expected, but we believe the sales trend is moving in the right direction. We reiterate our HOLD, but have lowered our target price to SEK5.5 (7).

Alexander Aukner
  • Alexander Aukner

Tighter supply…again

Biological challenges, El Niño, algae blooms, cold water temperatures, overproduction challenges and string-jellyfish have led us to cut our global supply estimates. We now expect 0.9–3.3% global growth for 2024–2025e, have raised our salmon prices to EUR7.9–8.0/kg (7.6–7.9), and have introduced our 2026 forecast of EUR8.1/kg. We reiterate our positive view on the sector, with Mowi and Austevoll Seafood our top picks.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch